Physician profile
Arvind A Kulkarni
NPI 1548210859
$4,681.30
in general payments reported to CMS, 2019-2025
37 companies · $801 in 2025
The $801 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $367 · 2021: $871 · 2022: $570 · 2023: $696 · 2024: $749 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,246.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,096.54 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $546.75 | 2019-2025 | Entyvio, Gattex |
| Intercept Pharmaceuticals, INC. | $318.77 | 2019-2024 | Ocaliva |
| Gilead Sciences, INC. | $238.33 | 2019-2023 | |
| Janssen Biotech, INC. | $228.46 | 2019-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.97 | 2019-2025 | Xifaxan, Plenvu |
| Genzyme Corporation | $216.71 | 2023-2025 | |
| Celgene Corporation | $169.10 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $158.49 | 2023-2025 | Voquezna |
| Pfizer INC. | $144.82 | 2019-2025 | |
| Lilly USA, LLC | $138.72 | 2023-2025 | Omvoh |
| Daiichi Sankyo INC. | $127.99 | 2020-2025 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $122.75 | 2023-2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $112.46 | 2019-2023 | Linzess |
| Janssen Scientific Affairs, LLC | $112.33 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $90.18 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $64.53 | 2019-2022 | |
| Ardelyx, INC. | $62.79 | 2024-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $58.87 | 2021-2022 | |
| Qol Medical, LLC | $49.63 | 2020-2021 | |
| Braintree Laboratories, INC. | $48.52 | 2019-2025 | Suflave, Sutab |
| Ferring Pharmaceuticals INC. | $46.52 | 2022-2023 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $37.04 | 2024 | Iqirvo |
| Redhill Biopharma INC. | $36.75 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $28.98 | 2023 | Idacio |
| Endo Pharmaceuticals INC. | $25.12 | 2019-2020 | |
| Boston Scientific Corporation | $21.26 | 2021 | |
| Mauna Kea Technologies, INC. | $19.92 | 2024 | |
| Ethicon US, LLC | $18.79 | 2022 | |
| Evoke Pharma, INC. | $17.34 | 2022 | |
| Vivus LLC | $17.20 | 2021 | |
| Aimmune Therapeutics, INC. | $17.05 | 2023 | |
| Amgen INC. | $16.19 | 2021 | |
| Intra-Sana Laboratories | $14.54 | 2021 | |
| Organon LLC | $13.45 | 2023 | Hadlima, Renflexis |
| Shionogi INC | $12.93 | 2019 | |
| Alfasigma USA, INC. | $12.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Kulkarni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.